Log In
Print this Print this

Priftin, rifapentine

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionRifamycin derivative
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentMarketed
Standard IndicationTuberculosis
Indication DetailsPrevent latent tuberculosis (TB) infection in HIV-infected adults; Prevent tuberculosis (TB) infection; Treat latent tuberculosis (TB) in patients <=2 years at high risk of progression to tuberculosis (TB); Treat tuberculosis (TB) infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today